Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies. The Company's technologies include AB569, MetaMx, MetaBlok, Borg and Arch Inflammation. AB569 is a drug candidate for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with Cystic Fibrosis. MetaMx is a synthetic molecule that targets brain tumor initiating cells and invasive glioma cells for the purpose of imaging, diagnosis and developing targeted therapies. MetaBlok is a drug candidate for the treatment of sepsis and cancer metastasis. Borg is a peptide-solid surface interface for binding peptides to solid surfaces to inhibit biofilm formation and reduce corrosion. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. The Company's subsidiaries include Arch Biotech Inc., Arch Biophysics Inc. and Arch Bio Ireland Ltd.